BeyondSpring
Open
$1.60
Prev. Close
$1.62
High
$1.62
Low
$1.57
Market Snapshot
$64.56M
-8.4
-0.51
44
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 44 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 44 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Recently from Cashu
BeyondSpring Enhances Cancer Treatment with Novel Immunotherapy Drug Development and Patient-Centered Trials
BeyondSpring Advances in Cancer Treatment with New Drug Development BeyondSpring Inc. makes significant strides in the advancement of cancer treatment through the continued development of its lead ass…
BeyondSpring Advances Cancer Treatment with Innovative Drug Plinabulin and Strategic Partnerships
BeyondSpring Sets New Standard in Cancer Treatment with Promising Drug Development BeyondSpring Inc., a clinical-stage biopharmaceutical company, focuses on the development of innovative cancer therap…
BeyondSpring Stock Update: Recent Developments and Market Trends
Sure! Please provide the text you'd like me to summarize into a 300-word article.
BeyondSpring's Stock Performance and Future Outlook: Key Insights and Analysis
Please provide the content you would like me to summarize, and I will create the article as requested.